Jun Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jun Jia has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Budong Zhu
Peking University Cancer Hospital and Institute
1 shared publication- Chao-Ying Wang
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Dongying Zhang
Department of Cardiovascular Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publication Guang-Lei Chang
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Yuanjiagang, Yuzhong, Chongqing 400016, P.R. China
1 shared publication- Guanming Jiang
Department of Thoracic Oncology, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital) , Dongguan, Guangdong, 523059
1 shared publication Guohong Song
Peking University Cancer Hospital and Institute
1 shared publication
Latest Publications
- Open Access
- 20 May 2022
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2022, 1-14
Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. This study aimed to evaluate the efficacy of PD-1/PD-L1 ICIs compared with chemotherapy for patients with lung cancer with BM. Electronic databases (PubMed, Embase, The Cochrane Library, and Web of Science) were searched. The meta-analysis assessed overall survival (OS) and progression-free survival (PFS) of the PD-1/PD-L1 inhibitors axis and its relationship with pathological type, drug modality, and the treatment line number in patients with BM from lung cancer. We included 694 patients with BM from lung cancer from 11 randomized controlled trials. Statistical analysis showed that compared with chemotherapy, PD-1/PD-L1 inhibitors could significantly prolong OS ( hazard ratio HR = 0.75 , 95 % confidence interval 95 % CI = 0.51 – 0.99 ) and PFS ( HR = 0.65 , 95 % CI = 0.51 – 0.80 ). In the subgroup analysis, ICIs plus chemotherapy improved PFS ( HR = 0.60 , 95 % CI = 0.40 – 0.80 ), but not OS ( HR = 0.75 , 95 % CI = 0.30 – 1.19 ). The efficacy of ICI monotherapy in patients with BM was significantly different between OS and PFS: OS pooled HR = 0.81 ( 95 % CI = 0.57 – 1.05 ) and PFS = 0.78 ( 95 % CI = 0.62 – 0.94 ). Among different pathological types, the OS pooled HR was 0.67 (9 5 % CI = 0.39 – 0.95 ) for non-small cell lung cancer (NSCLC) and 0.94 ( 95 % CI = 0.56 – 1.33 ) for small cell lung cancer (SCLC); the PFS pooled HR was 0.58 ( 95 % CI = 0.39 – 0.76 ) for NSCLC and 0.79 ( 95 % CI = 0.65 – 0.93 ) for SCLC. Subgroups analysis of treatment line showed that no advantage for OS with ICIs as first-line or subsequent-line therapy, whereas ICIs as first-line ( HR = 0.63 , 95 % CI = 0.53 – 0.74 ) and second-line ( HR = 0.62 , 95 % CI = 0.62 – 0.96 ) benefitted PFS. This meta-analysis implied that compared with chemotherapy, PD-1/PD-L1 inhibitors significantly improved efficacy treatment of patients with BM from lung cancer. Further studies are needed to confirm the role of ICIs in different pathological types and drug treatment modalities.
- 20 May 2022
- Published by Hindawi Limited in Journal of Immunology Research
- Vol. 2022, 1-14
Open AccessEfficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. This study aimed to evaluate the efficacy of PD-1/PD-L1 ICIs compared with chemotherapy for patients with lung cancer with BM. Electronic databases (PubMed, Embase, The Cochrane Library, and Web of Science) were searched. The meta-analysis assessed overall survival (OS) and progression-free survival (PFS) of the PD-1/PD-L1 inhibitors axis and its relationship with pathological type, drug modality, and the treatment line number in patients with BM from lung cancer. We included 694 patients with BM from lung cancer from 11 randomized controlled trials. Statistical analysis showed that compared with chemotherapy, PD-1/PD-L1 inhibitors could significantly prolong OS ( hazard ratio HR = 0.75 , 95 % confidence interval 95 % CI = 0.51 – 0.99 ) and PFS ( HR = 0.65 , 95 % CI = 0.51 – 0.80 ). In the subgroup analysis, ICIs plus chemotherapy improved PFS ( HR = 0.60 , 95 % CI = 0.40 – 0.80 ), but not OS ( HR = 0.75 , 95 % CI = 0.30 – 1.19 ). The efficacy of ICI monotherapy in patients with BM was significantly different between OS and PFS: OS pooled HR = 0.81 ( 95 % CI = 0.57 – 1.05 ) and PFS = 0.78 ( 95 % CI = 0.62 – 0.94 ). Among different pathological types, the OS pooled HR was 0.67 (9 5 % CI = 0.39 – 0.95 ) for non-small cell lung cancer (NSCLC) and 0.94 ( 95 % CI = 0.56 – 1.33 ) for small cell lung cancer (SCLC); the PFS pooled HR was 0.58 ( 95 % CI = 0.39 – 0.76 ) for NSCLC and 0.79 ( 95 % CI = 0.65 – 0.93 ) for SCLC. Subgroups analysis of treatment line showed that no advantage for OS with ICIs as first-line or subsequent-line therapy, whereas ICIs as first-line ( HR = 0.63 , 95 % CI = 0.53 – 0.74 ) and second-line ( HR = 0.62 , 95 % CI = 0.62 – 0.96 ) benefitted PFS. This meta-analysis implied that compared with chemotherapy, PD-1/PD-L1 inhibitors significantly improved efficacy treatment of patients with BM from lung cancer. Further studies are needed to confirm the role of ICIs in different pathological types and drug treatment modalities.
- Open Access
- 8 February 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (4) , 1554-1560
Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial
The present study compared the prognostic value of a marker, the C-terminal section of the arginine vasopressin prohormone (copeptin), with N-terminal B-type natriuretic peptide (NT-proBNP) in patients with severe acute decompensated heart failure. A prospective, observational cohort study was conducted in a tertiary care hospital and enrolled 129 patients with severe acute decompensated heart failure. Clinicians were blinded to investigational markers except NT-proBNP, and the study participants were followed up for 90 days. The end-point was a composite of cardiovascular death or re-hospitalization due to decompensated heart failure. Of the 129 patients enrolled, 47 reached the end-point and 82 were in a stable condition during follow-up. Receiver operating characteristic curve analysis revealed that the areas under curve for the prediction of adverse events within 90 days were similar for copeptin [0.602±0.052; 95% confidence interval (CI), 0.499–0.705], NT-proBNP (0.659±0.048; 95% CI, 0.565–0.753) and their combination (0.670±0.050; 95% CI, 0.573–0.767). Kaplan-Meier survival analysis showed that the predictive value of NT-proBNP regarding the probability of survival was superior compared with that of copeptin (log-rank test for trend, P=0.001 vs. 0.040). Furthermore, multivariate Cox proportional-hazards regression analysis revealed that increased NT-proBNP and copeptin plasma concentrations were significant independent predictors of adverse events. The present study provided evidence that copeptin has similar predictive properties compared with NT-proBNP regarding adverse events within 90-days in patients with severe acute decompensated heart failure, but that copeptin may not provide superior 90-day prediction compared to NT-proBNP.
- 8 February 2017
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (4) , 1554-1560
Open AccessComparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial
The present study compared the prognostic value of a marker, the C-terminal section of the arginine vasopressin prohormone (copeptin), with N-terminal B-type natriuretic peptide (NT-proBNP) in patients with severe acute decompensated heart failure. A prospective, observational cohort study was conducted in a tertiary care hospital and enrolled 129 patients with severe acute decompensated heart failure. Clinicians were blinded to investigational markers except NT-proBNP, and the study participants were followed up for 90 days. The end-point was a composite of cardiovascular death or re-hospitalization due to decompensated heart failure. Of the 129 patients enrolled, 47 reached the end-point and 82 were in a stable condition during follow-up. Receiver operating characteristic curve analysis revealed that the areas under curve for the prediction of adverse events within 90 days were similar for copeptin [0.602±0.052; 95% confidence interval (CI), 0.499–0.705], NT-proBNP (0.659±0.048; 95% CI, 0.565–0.753) and their combination (0.670±0.050; 95% CI, 0.573–0.767). Kaplan-Meier survival analysis showed that the predictive value of NT-proBNP regarding the probability of survival was superior compared with that of copeptin (log-rank test for trend, P=0.001 vs. 0.040). Furthermore, multivariate Cox proportional-hazards regression analysis revealed that increased NT-proBNP and copeptin plasma concentrations were significant independent predictors of adverse events. The present study provided evidence that copeptin has similar predictive properties compared with NT-proBNP regarding adverse events within 90-days in patients with severe acute decompensated heart failure, but that copeptin may not provide superior 90-day prediction compared to NT-proBNP.
- 17 March 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (7) , 1197-1203
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC. 79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ2 test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes. There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004). CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.
- 17 March 2012
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 138 (7) , 1197-1203
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness. We aimed to investigate whether allelic variants of cytochrome P450 (CYP450) affected objective response, progression-free survival (PFS), and overall survival (OS) in MBC. 79 SNPs in CYP450, whose minor allele frequency were ≥10%, were genotyped in 69 MBC patients who were treated with docetaxel plus capecitabine. Pearson’s χ2 test or Fisher’s exact test was used to investigate the influence of SNPs on objective response as appropriate. Log-rank test was used to assess the association between SNPs and survival outcomes. There is no significant association between polymorphisms and both objective response and OS. Only one SNP, CYP1A1 rs1048943 A>G (Ile462Val), was significantly associated with PFS (P = 0.0003). Multivariate analysis confirmed its prognostic significance for PFS (P = 0.004). CYP1A1 rs1048943 A>G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy in MBC patients. However, confirmatory study is needed to validate this finding.